CN1304412C - 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 - Google Patents
抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 Download PDFInfo
- Publication number
- CN1304412C CN1304412C CNB031562248A CN03156224A CN1304412C CN 1304412 C CN1304412 C CN 1304412C CN B031562248 A CNB031562248 A CN B031562248A CN 03156224 A CN03156224 A CN 03156224A CN 1304412 C CN1304412 C CN 1304412C
- Authority
- CN
- China
- Prior art keywords
- virus
- oligonucleotide
- cpg
- viruses
- chain rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241001493065 dsRNA viruses Species 0.000 title claims abstract description 28
- 241000700605 Viruses Species 0.000 claims abstract description 35
- 208000001490 Dengue Diseases 0.000 claims abstract description 21
- 206010012310 Dengue fever Diseases 0.000 claims abstract description 21
- 208000025729 dengue disease Diseases 0.000 claims abstract description 21
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 24
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 19
- 241000711573 Coronaviridae Species 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 10
- 241000711549 Hepacivirus C Species 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- -1 phosphorous acid acid amides triester Chemical class 0.000 claims description 7
- 241000710781 Flaviviridae Species 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 238000004073 vulcanization Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 21
- 208000035473 Communicable disease Diseases 0.000 abstract description 6
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 241000711557 Hepacivirus Species 0.000 abstract description 2
- 241000710843 Japanese encephalitis virus group Species 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 60
- 230000000694 effects Effects 0.000 description 27
- 239000012228 culture supernatant Substances 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000007170 pathology Effects 0.000 description 14
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000005289 controlled pore glass Substances 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GCHCDBOIRFPABI-UHFFFAOYSA-N NP(O)O.C1=NN=NN1.C1=NN=NN1 Chemical compound NP(O)O.C1=NN=NN1.C1=NN=NN1 GCHCDBOIRFPABI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (7)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031562248A CN1304412C (zh) | 2003-09-05 | 2003-09-05 | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 |
EP04762006A EP1650218B1 (en) | 2003-07-25 | 2004-07-26 | The artificial cpg single strand deoxidation oligonucleotide and its antiviral uses |
CA2533434A CA2533434C (en) | 2003-07-25 | 2004-07-26 | Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof |
PCT/CN2004/000863 WO2005014611A1 (fr) | 2003-07-25 | 2004-07-26 | Oligodesoxyribonucleotide a simple brin cpg artificiel et utilisations antivirales |
DE602004031946T DE602004031946D1 (de) | 2003-07-25 | 2004-07-26 | Das künstliche cpg single strand deoxidation-oligonukleotid und dessen antivirale anwendungen |
JP2006521375A JP4809220B2 (ja) | 2003-07-25 | 2004-07-26 | 人工合成CpG単鎖デオキシオリゴヌクレオチド及びその抗ウイルス作用 |
AT10174994T ATE532792T1 (de) | 2003-07-25 | 2004-07-26 | Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen |
AT04762006T ATE502949T1 (de) | 2003-07-25 | 2004-07-26 | Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen |
US10/565,718 US7491706B2 (en) | 2003-07-25 | 2004-07-26 | Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof |
EP10174994A EP2264046B1 (en) | 2003-07-25 | 2004-07-26 | Artificial CpG single-stranded oligodeoxynucleotide and antiviral use thereof |
KR1020067001765A KR101146203B1 (ko) | 2003-07-25 | 2004-07-26 | 인공합성한 CpG 단일가닥 올리고데옥시뉴클레오티드 및이의 항바이러스 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031562248A CN1304412C (zh) | 2003-09-05 | 2003-09-05 | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1590399A CN1590399A (zh) | 2005-03-09 |
CN1304412C true CN1304412C (zh) | 2007-03-14 |
Family
ID=34598351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031562248A Expired - Lifetime CN1304412C (zh) | 2003-07-25 | 2003-09-05 | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1304412C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100439386C (zh) * | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1847256B (zh) * | 2005-04-13 | 2011-06-15 | 长春华普生物技术有限公司 | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 |
CN102154290B (zh) * | 2011-01-12 | 2014-04-09 | 中国医学科学院病原生物学研究所 | 用于抑制流行性乙型脑炎病毒的siRNA |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1498895A (zh) * | 2003-05-28 | 2004-05-26 | 长春华普生物技术有限公司 | 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用 |
CN1526719A (zh) * | 2003-03-05 | 2004-09-08 | 长春华普生物技术有限公司 | 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸 |
CN1526718A (zh) * | 2003-03-05 | 2004-09-08 | 长春华普生物技术有限公司 | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 |
CN1569881A (zh) * | 2003-07-25 | 2005-01-26 | 长春华普生物技术有限公司 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
-
2003
- 2003-09-05 CN CNB031562248A patent/CN1304412C/zh not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1526719A (zh) * | 2003-03-05 | 2004-09-08 | 长春华普生物技术有限公司 | 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸 |
CN1526718A (zh) * | 2003-03-05 | 2004-09-08 | 长春华普生物技术有限公司 | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 |
CN1498895A (zh) * | 2003-05-28 | 2004-05-26 | 长春华普生物技术有限公司 | 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用 |
CN1569881A (zh) * | 2003-07-25 | 2005-01-26 | 长春华普生物技术有限公司 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100439386C (zh) * | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸 |
Also Published As
Publication number | Publication date |
---|---|
CN1590399A (zh) | 2005-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1608133A (zh) | 双链核糖核酸用于治疗正(+)链rna病毒感染的用途 | |
CN1203530A (zh) | 单独使用vx-478或者与azt或3tc联合使用治疗hiv引起的cns疾病 | |
CN1304412C (zh) | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 | |
CN1847256B (zh) | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 | |
CN1196480C (zh) | L-苏糖酸钙在制备预防或治疗骨折的药物中的用途 | |
CN1023295C (zh) | 预防和治疗病毒感染的方法和组合物 | |
CN1280303C (zh) | 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用 | |
CN100486987C (zh) | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 | |
JP4809220B2 (ja) | 人工合成CpG単鎖デオキシオリゴヌクレオチド及びその抗ウイルス作用 | |
CN1289520C (zh) | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 | |
CN1194986C (zh) | 丙型肝炎病毒高变区1合成肽及其应用 | |
RU2678332C1 (ru) | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения | |
CN1687033A (zh) | 一种抗呼吸道病毒的药物及用途 | |
RU2447899C2 (ru) | Композиция для лечения гепатита с и способ лечения гепатита с | |
Limthongkul et al. | Insect anionic septapeptides suppress DENV replication by activating antiviral cytokines and miRNAs in primary human monocytes | |
CN111346079B (zh) | 细菌dna促旋酶抑制剂brd7716作为治疗和/或预防登革病毒感染的药物及其制药用途 | |
JP2006514070A (ja) | C型肝炎及びウシウイルス性下痢のウイルスのようなフラビウイルス科に分類される種によって引き起こされる感染の治療に有用な二環式炭水化物化合物 | |
Sarkar et al. | Potential Drug Strategies to Target Coronaviruses | |
CN1293919C (zh) | 一种短棒状杆菌制剂或无细胞短棒状杆菌制剂在制备治疗hiv感染或爱滋病药剂中的应用 | |
Richert et al. | Mechanism of oncogenic transformation by Rous sarcoma virus II. Effect of rifampin on Rous sarcoma virus infection | |
Jain et al. | Antiviral Therapeutics | |
GB2625845A (en) | Use of ophiopogonin D in preparing anti-rotavirus medicament | |
CN1391954A (zh) | 增强核酸疫苗免疫的组合物及其生产方法和使用方法 | |
CN101073569A (zh) | 一种抗呼吸道病毒的药物及用途 | |
CN116115610A (zh) | 一种小分子抑制剂bci121在鱼类抗病毒中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: High tech Zone of Jilin province Changchun Chaoqun street 130103 No. 191 incubator building block A room 306 Patentee after: CHANGCHUN HUAPU BIOTECHNOLOGY CO.,LTD. Address before: 130021 Xinmin Street, Jilin, Changchun, China 4-28/1102-54 Patentee before: CHANGCHUN HUAPU BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 1208-1210, block B, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Industrial Development Zone, Nanjing, Jiangsu 210000 Patentee after: Nanjing Huapu Biotechnology Co.,Ltd. Address before: 130103 Room 306, Block A, Incubation Building, 191 Chaoqun Street, Changchun High-tech Zone, Jilin Province Patentee before: CHANGCHUN HUAPU BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Patentee after: Huapu Biotechnology (Jiangsu) Co.,Ltd. Address before: Room 1208-1210, block B, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Industrial Development Zone, Nanjing, Jiangsu 210000 Patentee before: Nanjing Huapu Biotechnology Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 051430 7-9/F, Building A2, No. 769, Taihang South Street, Shijiazhuang Hi tech Industrial Development Zone, Hebei Province Patentee after: Huapu Biotechnology (Hebei) Co.,Ltd. Address before: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Patentee before: Huapu Biotechnology (Jiangsu) Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070314 |